← Back to Search

Perflutren lipid microsphere for Kidney Cancer

Phase 2
Waitlist Available
Led By Emily Chang, MD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 18 years of age
A suspected diagnosis of kidney cancer with a solid or partially solid lesion and planned surgical nephrectomy within 3 months before surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline- up to 3 minutes
Awards & highlights

Study Summary

This trial will compare the accuracy of contrast-enhanced ultrasound, conventional ultrasound, and MRI in detecting kidney cancer lesions.

Eligible Conditions
  • Kidney Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline- up to 3 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline- up to 3 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. FR_a
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. FR_beta
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Volume
+11 more
Secondary outcome measures
3D CEUS Generated Metric in Kidney Mass - Tumor Stage vs. FR_a
3D CEUS Generated Metric in Kidney Mass - Tumor Stage vs. FR_beta
3D CEUS Generated Metric in Kidney Mass - Tumor Stage vs. Volume
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Perflutren Lipid Microsphere or LumasonExperimental Treatment2 Interventions
Patients with suspected kidney cancer and planned surgery will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perflutren lipid microsphere
2016
Completed Phase 2
~110
Sulfur hexafluoride lipid microspheres
2019
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
348 Previous Clinical Trials
88,219 Total Patients Enrolled
Emily Chang, MDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
1 Previous Clinical Trials
15 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Mar 2025